One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
Yuki OkadaKoji ObaNaoto FurukawaYoshimasa KosakaKenji OkitaSatoshi YukiYoshito KomatsuLuigi CelioMatti AaproPublished in: The oncologist (2019)
Although dexamethasone in combination with other antiemetic agents has been used to prevent chemotherapy-induced nausea and vomiting (CINV), it is of clinical importance to minimize total dose of dexamethasone in patients undergoing multiple cycles of emetogenic chemotherapy. This individual-patient-data meta-analysis from five randomized controlled trials (1,194 patients) demonstrated a noninferiority of the dexamethasone-sparing regimen for complete response and complete control of CINV. The outcomes were comparable across patients with different characteristics. These findings thus help physicians minimize use of the steroid and further reduce the burden of dexamethasone-related side effects in patients undergoing multiple consecutive courses of emetogenic chemotherapy.
Keyphrases
- chemotherapy induced
- patients undergoing
- systematic review
- high dose
- low dose
- meta analyses
- end stage renal disease
- randomized controlled trial
- case report
- chronic kidney disease
- ejection fraction
- electronic health record
- big data
- clinical trial
- prognostic factors
- squamous cell carcinoma
- metabolic syndrome
- radiation therapy
- data analysis
- risk factors
- insulin resistance